A new option for young migraineurs - Pain News Network

35 adolescent migraine patients aged 12 to 17 years took part in the two-month comparative study. Over-the-counter drugs and oral triptans were used by patients during medication month and Nerivio during Remote Electrical Neuromodulation (REN) month.

Two hours after treatment, over a third (37%) of patients achieved complete freedom from pain during the REN phase of the study, compared to just 8.6% in the medication phase. Some degree of pain relief was reported by 80% of patients in the REN phase as opposed to 57% in the medication phase.

“This study provides evidence that Nerivio can be considered the acute treatment of first choice, especially for adolescents with drug-limiting comorbidities or a preference for non-drug treatment,” said co-author Samantha Irwin, MD, a pediatric neurologist at UCSF Benioff Children’s Hospital in San Francisco. “The importance of a non-pharmacological, discreet, easy-to-use and effective acute treatment in youth armaments cannot be emphasized enough.”

Long-term effects of childhood migraines

Early treatment for childhood migraines is important as there is increasing evidence that repeated headache attacks in children reduce the build-up of “gray matter” in parts of the brain that process pain signals, leading to more frequent and severe migraines in adults.

“We have conducted studies here, independently of pharmaceutical companies, in which we have shown that the sooner we can intervene with effective therapy and education of patients, the better their long-term results are,” Hershey told PNN. “So we really have the opportunity to intervene with a child or young person who can influence them in their lives.

“A device can be as effective as a drug. What I am telling patients is that they are in control of themselves. Instead of taking a drug and hoping it will work, they actually control the device with their smartphone and can really get their headaches under control, which is what we ultimately expect from them. ”

Nerivio is only available on prescription and is eligible for insurance. When purchased wholesale, the list price is $ 599 for a twelve treatment unit, although buyers can save money by signing up for a patient savings program, depending on insurance coverage.

Theranica is currently recruiting patients for a placebo-controlled study to see if Nerivio could be effective in preventing migraines. The company is also investigating whether the device can help treat other chronic pain conditions in addition to migraines.

According to the American Migraine Foundation, migraines affect more than 37 million people in the United States. In addition to headaches, migraines can cause nausea, blurring, or visual disturbances, as well as sensitivity to light and noise. Women are three times more likely to have migraines than men.